ISSN: 1859 - 2872
The efficacy of low-dose 131-I in post-total thyroidectomy differentiated thyroid carcinoma at Vietnam National Cancer Hospital
Main Article Content
Keywords
I-131, Thyroid cancer, thyroid remnant ablation
Abstract
Objective: To evaluate the efficacy of low-dose of 30mCi I-131 (outpatient dose) to ablate residual thyroid tissue and serum thyroglobulin reduction in patients with low-risk differentiated thyroid cancer after total thyroidectomy at K Hospital. Subject and method: Retrospective study on 150 patients treated with 30mCi I-131 dose from January 2020 to June 2021. Result: The study included 139 female patients (93.7%), 11 male patients (7.3%), 27 to 74 years old, average 51 ± 10 years olds, 89 patients (59.3%) < 55 years old, 61 patients (40.7%) over 55 years old. Successful thyroid tissue ablation was achieved in 120 patients (80%), serum thyroglobulin before treatment was 2.33 ± 7.07ng/ml, after treatment was 1.20 ± 6.77, the reduction of serum thyroglobulin before and after treatment was statistically significant (p=0.006). Conclusion: Dose of 30mCi has a good efficacy for thyroid tissue remnant ablation for patients with low risk factors.
Article Details
References
1. Vardarli I, Weidemann F, Aboukoura M, Herrmann K, Binse I, Görges R (2020) Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: A meta-analysis. BMC Cancer 20: 550. https://doi.org/10.1186/s12885-020-07029-3.
2. Li F, Li W, Gray KD, Zarnegar R, Wang D, Fahey TJ 3rd (2020) Ablation therapy using a low dose of radioiodine may be sufficient in low-to intermediate-risk patients with follicular variant papillary thyroid carcinoma. DOI: 10.1177/0300060520966491.
3. Chung SR, Baek JH, Choi YJ, Lee JH (2019) Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. European Society of Radiology. https://doi.org/10.1007/s00330-019-06063-5.
4. Jeong SY, Lee SW, Kim WW et al (2019) Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy. Scientific Reports 9:5570. https://doi.org/10.1038/s41598-019-42083-3.
5. Jimenez Londoño GA, Garcia Vicente AM, Sastre Marcos J, Pena Pardo FJ, Amo-Salas M, Moreno Caballero M, Talavera Rubio MP, Gonzalez Garcia B, Disotuar Ruiz ND, Soriano Castrejón AM (2018) Low-dose radioiodine ablation in patients with low-risk differentiated thyroid cancer. European Thyroid Association, DOI: 10.1159/000489850.
6. Peiris AN, Medlock D, Gavin M (2019) Thyroglobulin for monitoring for thyroid cancer recurrence. JAMA 321(12): 1228. doi:10.1001/jama.2019.0803.
7. Indrasena BS (2017) Use of thyroglobulin as a tumour marker. World J Biol Chem 8(1): 81-85.
8. Lv RB, Wang QG, Liu C, Liu F, Zhao Q, Han JG, Ren DL, Liu B, Li CL (2017) Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer. OncoTargets and Therapy 10: 4051-4057.
9. Wagieh Sh, Al Salman Kh, Munshy T, El Refaei Sh, Abd- El Kareem M, and Abd-El Razek Sh (2012) Successful complete ablation rate post a second ablation dose of 30mCi radioactive Iodine (I-131) in patients with papillary thyroid cancer. Egyptian J. Nucl. Med 5(1).
10. Ibrahim DR, Kelany MR, Michael MM, and Elsayed ZM (2016) Low-dose versus high-dose radioactive iodine ablation of differentiated thyroid carcinoma: A prospective randomized study. International Journal of Cancer Therapy and Oncology, December.
11. Yasmin T, Adnan S, Younis MN, Fatima A, Shahid A (2021) Comparing high and low-dose radio-iodine therapy in thyroid remnant ablation among intermediate and low-risk papillary thyroid carcinoma patients single centre experience. Dose-response: An international journal: 1-7.
12. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 88(4): 1433-1441. doi: 10.1210/ jc.2002-021702.
13. Couto JS, Almeida MFO, Trindade VCG, Marone MMS, Scalissi NM, Cury AN, Ferraz C, Padovani RP (2020) A cutoff thyroglobulin value suggestive of distant metastases in differentiated thyroid cancer patients. Brazilian Journal of Medical and Biological Research 53(11): 9781
2. Li F, Li W, Gray KD, Zarnegar R, Wang D, Fahey TJ 3rd (2020) Ablation therapy using a low dose of radioiodine may be sufficient in low-to intermediate-risk patients with follicular variant papillary thyroid carcinoma. DOI: 10.1177/0300060520966491.
3. Chung SR, Baek JH, Choi YJ, Lee JH (2019) Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. European Society of Radiology. https://doi.org/10.1007/s00330-019-06063-5.
4. Jeong SY, Lee SW, Kim WW et al (2019) Clinical outcomes of patients with T4 or N1b well-differentiated thyroid cancer after different strategies of adjuvant radioiodine therapy. Scientific Reports 9:5570. https://doi.org/10.1038/s41598-019-42083-3.
5. Jimenez Londoño GA, Garcia Vicente AM, Sastre Marcos J, Pena Pardo FJ, Amo-Salas M, Moreno Caballero M, Talavera Rubio MP, Gonzalez Garcia B, Disotuar Ruiz ND, Soriano Castrejón AM (2018) Low-dose radioiodine ablation in patients with low-risk differentiated thyroid cancer. European Thyroid Association, DOI: 10.1159/000489850.
6. Peiris AN, Medlock D, Gavin M (2019) Thyroglobulin for monitoring for thyroid cancer recurrence. JAMA 321(12): 1228. doi:10.1001/jama.2019.0803.
7. Indrasena BS (2017) Use of thyroglobulin as a tumour marker. World J Biol Chem 8(1): 81-85.
8. Lv RB, Wang QG, Liu C, Liu F, Zhao Q, Han JG, Ren DL, Liu B, Li CL (2017) Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer. OncoTargets and Therapy 10: 4051-4057.
9. Wagieh Sh, Al Salman Kh, Munshy T, El Refaei Sh, Abd- El Kareem M, and Abd-El Razek Sh (2012) Successful complete ablation rate post a second ablation dose of 30mCi radioactive Iodine (I-131) in patients with papillary thyroid cancer. Egyptian J. Nucl. Med 5(1).
10. Ibrahim DR, Kelany MR, Michael MM, and Elsayed ZM (2016) Low-dose versus high-dose radioactive iodine ablation of differentiated thyroid carcinoma: A prospective randomized study. International Journal of Cancer Therapy and Oncology, December.
11. Yasmin T, Adnan S, Younis MN, Fatima A, Shahid A (2021) Comparing high and low-dose radio-iodine therapy in thyroid remnant ablation among intermediate and low-risk papillary thyroid carcinoma patients single centre experience. Dose-response: An international journal: 1-7.
12. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism 88(4): 1433-1441. doi: 10.1210/ jc.2002-021702.
13. Couto JS, Almeida MFO, Trindade VCG, Marone MMS, Scalissi NM, Cury AN, Ferraz C, Padovani RP (2020) A cutoff thyroglobulin value suggestive of distant metastases in differentiated thyroid cancer patients. Brazilian Journal of Medical and Biological Research 53(11): 9781
Article Sidebar
Published
Sep 29, 2023
Section
Articles
How to Cite
BìnhD. Đức, TânN. T., VănN. Q., & SơnP. L. (2023). The efficacy of low-dose 131-I in post-total thyroidectomy differentiated thyroid carcinoma at Vietnam National Cancer Hospital. Tạp Chí Y Dược lâm sàng 108, 18(YHHN). https://doi.org/10.52389/ydls.v18iYHHN.1921